Researchers have been exploring the use of stem cell therapeutics for the treatment of severe conditions such as type 1 diabetes, Alzheimer’s disease and Muscular Dystrophy. There are several types of stem cells that scientists think may be used in different ways to develop treatments for muscular dystrophy. The main stem-cell-based approaches…
Researchers at Royal Victoria Infirmary and the Institute of Genetic Medicine in the United Kingdom recently conducted a review on the short stature and delayed puberty often seen in patients with Duchenne muscular dystrophy (DMD). The study was published in the journal Archives of Disease…
Fairfax, Virginia based eye tracking software developer LC Technologies, and screen protector and glare-elimination technology specialists NuShield, Inc. of Newtown, Pennsylvania ate teaming up to bring communication mobility to disabled patients who are unable to communicate via speech or hand motion. Eye tracking is the field of monitoring…
A scientist who helped develop a pioneering treatment recently expressed her frustration after the NHS refused funding of Translarna for the treatment of Duchenne Muscular Dystrophy. Translarna has recently become the first Duchenne Muscular Dystrophy targeting therapy to receive approval by the European Medicines Agency (EMA). The drug is available in many…
Researchers at the University of Oxford in the United Kingdom recently published in the journal Experimental Physiology a review on the recent progress in genetic based therapies for Duchenne muscular dystrophy (DMD). The study is entitled “Advances in genetic therapeutic strategies for Duchenne…
Myotonic muscular dystrophy type 1 is a chronic and slowly progressing genetic disease affecting many organs. It is the most frequent form of muscular dystrophy and, as the name implies, is characterized by wasting of the muscles throughout the body. Nevertheless, the genetic defect on the myotonic dystrophy protein kinase also…
Massachusetts based Catabasis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on their proprietary pathway pharmacology technology platform, recently announced that they have begun treating patients in their MoveDMD trial, a Phase 1/2 trial of CAT- 1004 for the treatment of Duchenne…
Grace Century’s bio banking project, Provia Laboratories, LLC, a healthcare services company specializing in high-quality bio-banking (the collection, transport, processing and cryogenic storage of biological specimens), recently reported 47% quarterly growth in enrollments for their Store-a-Tooth™ cryogenic storage service of dental stem cells. Store-A-Tooth is committed to offering…
Akashi Therapeutics Inc. a biopharmaceutical company focused on developing treatments for patients with Duchenne muscular dystrophy (DMD) recently announced encouraging interim results of its ongoing Phase 1b/2a clinical trial of HT-100 (delayed-release halofuginone) an orally available small molecule to reduce inflammation and fibrosis while promoting the regeneration of…
Researchers at UCL Institute of Child Health in the United Kingdom reported new insights into muscle stem cell transplantation therapy in muscular dystrophy mouse models. The study was recently published in the journal Skeletal Muscle and is entitled “The effect of the muscle…
Get regular updates to your inbox.